These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24190033)

  • 1. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis.
    Nishioka Y; Azuma M; Kishi M; Aono Y
    J Med Invest; 2013; 60(3-4):175-83. PubMed ID: 24190033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
    Pietras K; Pahler J; Bergers G; Hanahan D
    PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast.
    Gharaee-Kermani M; Hu B; Phan SH; Gyetko MR
    Curr Med Chem; 2009; 16(11):1400-17. PubMed ID: 19355895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
    Iwayama T; Olson LE
    Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGF receptors as targets in tumor treatment.
    Ostman A; Heldin CH
    Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
    Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
    Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
    Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
    Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-derived growth factor in idiopathic pulmonary fibrosis.
    Antoniades HN; Bravo MA; Avila RE; Galanopoulos T; Neville-Golden J; Maxwell M; Selman M
    J Clin Invest; 1990 Oct; 86(4):1055-64. PubMed ID: 2170444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib].
    Kameda H
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):77-84. PubMed ID: 19404005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.
    Andrianifahanana M; Wilkes MC; Gupta SK; Rahimi RA; Repellin CE; Edens M; Wittenberger J; Yin X; Maidl E; Becker J; Leof EB
    FASEB J; 2013 Nov; 27(11):4444-54. PubMed ID: 23913859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis.
    Aono Y; Kishi M; Yokota Y; Azuma M; Kinoshita K; Takezaki A; Sato S; Kawano H; Kishi J; Goto H; Uehara H; Izumi K; Nishioka Y
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):793-801. PubMed ID: 24885373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-specific expression of runt-related transcription factor 2 contributes to pulmonary fibrosis.
    Mümmler C; Burgy O; Hermann S; Mutze K; Günther A; Königshoff M
    FASEB J; 2018 Feb; 32(2):703-716. PubMed ID: 28986417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.
    Xu X; Dai H; Wang C
    Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
    Grimminger F; Günther A; Vancheri C
    Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.